Published in
Karger Publishers, Dementia and Geriatric Cognitive Disorders, 1-2(36), p. 99-110, 2013
DOI: 10.1159/000353442
Links
Tools
Evaluation of the Cerebrospinal Fluid Amyloid-�1-42/Amyloid-�1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
,
Kaj Blennow,
Annika Öhrfelt,
Oskar Hansson,
Annika Ohrfelt
Full text: Download
Abstract
<b><i>Background:</i></b> The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-β (Aβ)<sub>1-42</sub>/Aβ<sub>1-40</sub> ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. <b><i>Method:</i></b> CSF levels of Aβ<sub>1-40</sub> and Aβ<sub>1-42</sub> in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. <b><i>Results:</i></b> The CSF Aβ<sub>1-42</sub>/Aβ<sub>1-40</sub> ratio increased discrimination of AD from PDD and DLB compared with either of the two Aβ biomarkers individually. <b><i>Conclusion:</i></b> The use of the Aβ<sub>1-42</sub>/Aβ<sub>1-40</sub> ratio could improve the differentiation of AD from PDD and DLB.